Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SULAR vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nisoldipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle. This leads to vasodilation, reduced peripheral vascular resistance, and decreased myocardial oxygen demand.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Management of hypertension, alone or in combination with other antihypertensive agents
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
10-20 mg orally once daily; maximum 60 mg/day.
Intravenous: 500 mg every 6 hours.
Terminal half-life of 24-50 hours, mean ~34 hours; extended in elderly and hepatic impairment, dose adjustment may be needed
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Extensively metabolized in the liver via CYP3A4; undergoes first-pass metabolism. Metabolites are inactive.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Renal: 50-60% as metabolites, 10% as unchanged drug; Fecal: ~35%; Biliary: <5%
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
>95% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
3-10 L/kg; extensive tissue distribution, slow equilibration
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Oral: 65-90% (first-pass metabolism); extended-release formulation provides consistent absorption
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
No adjustment for GFR ≥30 m L/min. For GFR <30 m L/min, initiate at 5 mg once daily.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh A: 5 mg once daily. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Safety and efficacy not established; no approved dosing.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Initiate at 5 mg once daily; titrate cautiously due to increased sensitivity and risk of hypotension.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
None
None
Increased angina and/or myocardial infarction upon initiation or dose titration; caution in patients with heart failure, aortic stenosis, or significant left ventricular dysfunction; may cause hypotension; caution in patients with hepatic impairment; grapefruit juice increases nisoldipine levels and should be avoided; drug interactions with CYP3A4 inhibitors and inducers.
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Hypersensitivity to nisoldipine or any dihydropyridine calcium channel blocker; concomitant administration with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir).
None
Avoid grapefruit and grapefruit juice as they increase nisoldipine serum concentrations by inhibiting CYP3A4 metabolism. Concomitant intake of high-fat meals (e.g., >50% fat) can increase the rate and extent of absorption; advise taking consistently with or without food. St. John's wort may reduce efficacy due to CYP3A4 induction.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
Pregnancy Category C. First trimester: No adequate studies; potential for fetal harm based on animal data. Second and third trimesters: Risk of fetal hypotension, oligohydramnios, and neonatal renal failure. Avoid use during pregnancy unless benefit outweighs risk.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Excreted in human milk; M/P ratio unknown. Effects on infant unknown. Use with caution, especially in preterm infants or those with compromised renal function.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
Increased plasma volume and hepatic metabolism in pregnancy may require dose increase. Monitor clinical response and titrate accordingly.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
Nisoldipine (Sular) is a dihydropyridine calcium channel blocker with high vascular selectivity; avoid use in patients with unstable angina or recent MI due to reflex tachycardia risk. Do not administer with grapefruit juice as it significantly increases drug exposure. Monitor for peripheral edema, especially in the elderly. Use cautiously in patients with severe aortic stenosis or hepatic impairment. May be taken without regard to meals, but avoid high-fat meals which can increase absorption.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take exactly as prescribed; do not crush or chew extended-release tablets.,Avoid grapefruit and grapefruit juice while taking this medication.,Do not stop abruptly without consulting your doctor; may worsen chest pain or blood pressure.,You may experience dizziness or lightheadedness; rise slowly from sitting or lying positions.,Notify your doctor if you develop swelling in your ankles or feet, rapid heartbeat, or severe dizziness.,Avoid alcohol as it can increase the risk of low blood pressure and dizziness.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SULAR vs AMVAZ, answered by our medical review team.
SULAR is a Calcium Channel Blocker that works by Nisoldipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle. This leads to vasodilation, reduced peripheral vascular resistance, and decreased myocardial oxygen demand.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SULAR and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SULAR is: 10-20 mg orally once daily; maximum 60 mg/day.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SULAR and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SULAR is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; potential for fetal harm based on animal data. Second and third trimesters: Risk of fetal hypotension, oligohydramnios, . AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.